Rapport Therapeutics announces $234.7M public offering of 9.6M shares at $26.00 per share

Rapport Therapeutics, Inc.

Underwriting agreement for 9,615,385 shares at $26.00; underwriters option for up to 1,442,307 additional shares.
Net proceeds estimated at $234.7 million (excluding over-allotment).
Proceeds to fund RAP-219 clinical trials, R&D, and working capital.
Closing expected on or about September 11, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.